Associative Stimulation of the Supraorbital Nerve Fails to Induce Timing-Specific Plasticity in the Human Blink Reflex

Zeuner, Kirsten E.; Knutzen, Arne; Al-Ali, Asmaa; Hallett, Mark; Deuschl, Günther; Bergmann, Til O.; Siebner, Hartwig R.
October 2010
PLoS ONE;2010, Vol. 5 Issue 10, p1
Academic Journal
Background: Associative high-frequency electrical stimulation (HFS) of the supraorbital nerve in five healthy individuals induced long-term potentiation (LTP)-like or depression (LTD)-like changes in the human blink reflex circuit according to the rules of spike timing-dependent plasticity (Mao and Evinger, 2001). HFS given at the onset of the R2 component of the blink reflex (HFSLTP) produced a lasting facilitation of the R2, whereas HFS given shortly before R2 (HFSLTD) caused a lasting suppression of the R2. In patients with benign essential blepharospasm (BEB), a focal dystonia affecting the orbicularis oculi muscles, HFSLTP induced excessive LTP-like associative plasticity relative to healthy controls, which was normalized after botulinum toxin (BTX) injections (Quartarone et al, 2006). Methodology/Principal Findings: We used HFS conditioning of the supraorbital nerve to study homeostatic metaplasticity of the blink reflex circuit in healthy subjects and dystonic patients. On separate days, we tested the conditioning effects on the R2 response and paired-pulse R2 inhibition after (i) HFSLTP, (ii) HFSLTP followed by HFSLTP, and (iii) HFSLTP followed by HFSLTD. Controls also received (iv) HFSLTD alone and (v) a non-intervention protocol. In BEB patients, HFSLTP followed by HFSLTD was given before and after BTX treatment. We were not able to replicate the bidirectional timing-dependent effects of HFSLTP and HFSLTD alone. All HFS protocols produced a non-specific reduction of the R2 response and a relative decrease in paired-pulse inhibition. These R2 changes also occurred in controls when no HFS was applied. There was also no trace of a homeostatic response pattern in BEB patients before or after BTX treatment. Conclusion/Significance: Our data challenge the efficacy of associative HFS to produce bidirectional plasticity in the human blink reflex circuit. The non-specific decrease of the R2 response might indicate habituation of the blink reflex following repeated electrical supraorbital stimulation. The increase of inhibition after paired pulse stimulation might reflect homeostatic behaviour to prevent further down regulation of the R2 response to preserve the protection of this adverse-effects reflex.


Related Articles

  • Botulinum Toxin Physiology in Focal Hand and Cranial Dystonia. Karp, Barbara Illowsky // Toxins;Nov2012, Vol. 4 Issue 11, p1404 

    The safety and efficacy of botulinum toxin for the treatment of focal hand and cranial dystonias are well-established. Studies of these adult-onset focal dystonias reveal both shared features, such as the dystonic phenotype of muscle hyperactivity and overflow muscle contraction and divergent...

  • Botulinum toxin type B de novo therapy of cervical dystonia. Dressler, Dirk; Bigalke, Hans // Journal of Neurology;Aug2005, Vol. 252 Issue 8, p904 

    Botulinum toxin induced therapy failure type B antibody (BT–B, BT–B–AB) has so far only been reported after previous formation of antibodies against botulinum toxin type A (BT–A, BTA– AB).We wanted to explore the risk of BT-B-AB-induced therapy failure in...

  • Botulinum information.  // British Journal of Community Nursing;Dec2005, Vol. 10 Issue 12, p581 

    The article presents information about a leaflet entitled "Botulinum Toxin: Your Questions Answered," from Ipsen Ltd for people with dystonias. It was initially developed to help the Dystonia Society, the organization dedicated to support of people affected by dystonia, answer questions from...

  • Neuroleptic-Induced Tardive Cervical Dystonia: Clinical Series of 20 Patients. Godeiro-Junior, Clecio; Felício, Andre C.; de Carvalho Aguiar, Patrícia; Borges, Vanderci; Silva, Sonia M. A.; Ferraz, Henrique B. // Canadian Journal of Neurological Sciences;Mar2009, Vol. 36 Issue 2, p222 

    Background: Cervical dystonia (CD) may be classified according to the underlying cause into primary or secondary CD. Previous exposure to neuroleptics is one of the main causes of adult-onset secondary dystonia. There are few reports that characterize the clinical features of primary CD and...

  • Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature. Giokzoglou, T.; Cordivari, C.; Lee, P. J.; Hanna, M. G.; Lees, A. J. // Journal of Neurology, Neurosurgery & Psychiatry;Nov2005, Vol. 76 Issue 11, p1594 

    Botulinum toxin type A (BTXA) is widely used in neurological therapeutics for a variety of indications such as dystonia, spasticity, hyperhidrosis, and hypersalivation. It is relatively contraindicated in disorders of neuromuscular transmission, in individuals with known hypersensitivity or...

  • Glucose hypermetabolism in the thalamus of patients with essential blepharospasm. Suzuki, Y.; Mizoguchi, S.; Kiyosawa, M.; Mochizuki, M.; Ishiwata, K.; Wakakura, M.; Ishii, K. // Journal of Neurology;Jul2007, Vol. 254 Issue 7, p890 

    Essential blepharospasm (EB) is classified as a form of focal dystonia characterized by involuntary spasms of the musculature of the upper face. The basic neurological process causing EB is not known. The purpose of this study was to investigate cerebral glucose metabolism in patients with EB...

  • Feasibility of Video Clip Analysis on Effect of Botulinum Toxin-A Injection for Post-Stroke Upper Limb Spasticity. Woo-Jin Kim; Kumthornthip, Witsanu; Byung Mo Oh; Eun Joo Yang; Nam-Jong Paik // Toxins;May2013, Vol. 5 Issue 5, p983 

    Existing functional evaluation tools do not accurately reveal the improved function following botulinum toxin A (BTX-A) injection for post-stroke upper limb spasticity. With the aim of developing an alternate method of measuring functional improvement following BTX-A injection, this study tested...

  • Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. Müller, J.; Wenning, G. K.; Wissel, J.; Seppi, K.; Poewe, W. // Journal of Neurology;Mar2002, Vol. 249 Issue 3, p300 

    We investigated the efficacy of botulinum toxin A (BtxA) therapy in patients with atypical parkinsonian disorders (APD) exhibiting different types of disabling focal dystonia unresponsive to oral drug therapy. Eight patients with functionally disabling focal dystonia out of a series of 60...

  • Botulinum toxin for writer's cramp: a randomised, placebo- controlled trial and 1-year follow-up. Kruisdijk, J. J. M.; Koelman, J. H. T. M.; de Visser, B. W. Ongerboer; de Haan, R. J.; Speelman, J. D. // Journal of Neurology, Neurosurgery & Psychiatry;Mar2007, Vol. 78 Issue 3, p264 

    Background: Botulinum toxin type A (BoNT-A) has become the treatment of choice for most types of focal dystonia. Objective: To investigate the efficacy of BoNT-A injections in patients with writer's cramp in a double-blind, randomised, placebo-controlled trial and to evaluate the follow-up...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics